IM体育抽注买球

February 16, 2016
https://www.tripleiconsulting.com/wp-content/uploads/2013/08/fdalogo.jpg

The Food and Drug Administration of the Philippines (FDA) reminds all concerned Pharmaceutical Companies to indicate the Global Product Identification Number (GPIN) and an establishment number on their products.

GPIN is a unique reference issued by international organizations and is being implemented in over 100 countries worldwide. This standard of measure is recognized by the World Customs Organization and the World Health Organization to help the fight against counterfeit products.

The implementation of GPIN also helps to lessen the processing time in clearing products when facilitating trade. If a product is imported from a foreign manufacturer, the local distributor will not need to apply for a new GPIN since the product would have an internationally recognized GPIN already. In this case, to comply with the requirements, an establishment number should be obtained.

However, if a drug product is manufactured locally, the local drug establishment must join a global standards organization to obtain their establishment identification number and be provided with GPIN for their products.

On June 30, 2016, all products must be labeled with a barcode or a QR Code corresponding to its respective GPIN. Also part of the label is the batch and lot number together with the expiry date.

Contact us

Contact us below by filling out the form or just email us a message using the email info@tripleiconsulting.com

First Name (required)

Last Name (required)

Your Email (required)

Phone (Enter Your Phone Number if You'd Like Us to Call You)

Your Message

Enter the Captcha
Reload

友情链: IM体育数据最新版分析|预测推荐|IM体育现场视频比赛 | 2022im体育网上赛事_预测滚球_2022im体育结果回放时间 | im体育电脑版_分析官方赛事_im体育开户买球 | 2022im体育直播赛程官网|im体育的虚拟比赛技巧|2022im体育app赛事在线 | im体育电竞app|IM体育半决赛最新直播|IM体育正规版 | IM·体育平台官网_期胜负彩推荐_IM·体育盘口手机版 | 2022im体育软件注册可靠|v10.8 IOS版|2022im体育免费在线 |